Extending natalizumab up to 8 weeks shown safe and effective in patients with MS

(NYU Langone Medical Center / New York University School of Medicine) Extending the dose of natalizumab from four weeks up to eight weeks was shown to be well-tolerated and effective in patients, and resulted in no cases of the potentially fatal side effect progressive multifocal leukoencephalopathy.